Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

March 31, 2028

Conditions

Pancreas Cancer

Interventions

DRUG

Bortezomib Injection

Bortezomib Injection, a kind of chemotherapy drug

DRUG

Sintilimab

PD-1 antibody

DRUG

mFOLFIRINOX

Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium

Trial Locations (1)

RECRUITING

First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou

All Listed Sponsors

lead

Zhejiang University

OTHER